U-Neuron Biomedical (ROCO:6973) ROCE %: -7.97% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6973 U-Neuron Biomedical Inc ROCO:6973
32 GF Score
Price NT$41.35
GF Value NT$70.22
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is U-Neuron Biomedical ROCE %?

U-Neuron Biomedical ROCO:6973 +4.68% 32 ROCE % is -7.97% as of Jun. 2026. GuruFocus rates ROCO:6973 with a GF Score™ of 32/100 and a GF Value™ of NT$70.22 (Possible Value Trap). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. U-Neuron Biomedical's annualized ROCE % for the quarter that ended in Jun. 2026 was -7.97%.

U-Neuron Biomedical  (ROCO:6973) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

U-Neuron Biomedical ROCE % Related Terms

U-Neuron Biomedical ROCE % Historical Data

* Premium members only.

The historical data trend for U-Neuron Biomedical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

U-Neuron Biomedical ROCE % Chart

U-Neuron Biomedical Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -8.49 -23.95 -25.66 -9.12 -7.12

U-Neuron Biomedical Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -13.40 -8.62 -5.90 -8.49 -7.97
ROCO:6973
32GF Score
U-Neuron Biomedical Inc ROCO:6973
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

U-Neuron Biomedical ROCE % Calculation

U-Neuron Biomedical's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-54.665/( ( (846.674 - 34.526) + (763.514 - 39.117) )/ 2 )
=-54.665/( (812.148+724.397)/ 2 )
=-54.665/768.2725
=-7.12 %

U-Neuron Biomedical's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Dec. 2025 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Dec. 2025 )(Q: Jun. 2026 )
=-56.528/( ( (763.514 - 39.117) + (755.06 - 61.251) )/ 2 )
=-56.528/( ( 724.397 + 693.809 )/ 2 )
=-56.528/709.103
=-7.97 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -7.97% mean?
U-Neuron Biomedical (ROCO:6973) has a ROCE % of -7.97% as of Jun. 2026.
Is U-Neuron Biomedical's ROCE % too high?
U-Neuron Biomedical's current ROCE % is -7.97%. Overall, U-Neuron Biomedical has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does U-Neuron Biomedical's ROCE % compare to VRTX and REGN?
U-Neuron Biomedical's ROCE % of -7.97% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. U-Neuron Biomedical's current ROCE % is -7.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is U-Neuron Biomedical stock overvalued right now?
Based on GuruFocus' analysis, U-Neuron Biomedical (ROCO:6973) is currently considered Possible Value Trap. The stock's GF Value™ is NT$70.22, compared to a current price of NT$41.35 — trading 41.1% below its estimated fair value. The current ROCE % is -7.97%. U-Neuron Biomedical's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For U-Neuron Biomedical (ROCO:6973), the current ROCE % is -7.97% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is U-Neuron Biomedical (ROCO:6973) Overvalued in 2026?

Based on GuruFocus' analysis, U-Neuron Biomedical stock appears to be undervalued. The current stock price of NT$41.35 is trading 41.1% below its estimated GF Value™ of NT$70.22. GuruFocus considers U-Neuron Biomedical to be Possible Value Trap.

Key valuation signals for ROCO:6973:

  • ROCE %: -7.97%
  • GF Value™: NT$70.22 vs. price of NT$41.35 (41.1% below fair value)
  • GF Score™: 32/100 with 3 warning signs

No single metric tells the full story. See the ROCO:6973 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

U-Neuron Biomedical Business Description

Address Xintai 5th Road, 18th Floor-5, No. 99, Section. 1, Xizhi District, New Taipei City, TWN, 22175
U-Neuron Biomedical Inc is engaged in research and development of stem cell storage & separation technology, and treatment application technology. It has patent on the Technology of Culture and Isolation of Amniotic Fluid Stem Cell.
32GF Score

Get the complete analysis for ROCO:6973

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$41.35
Price
NT$70.22
GF Value